SK Biopharm Takes Epilepsy Drug to Brazil in Latin America Expansion

Korea's Pharmaceutical Push South

SK Biopharmaceuticals announced Wednesday it will introduce Cenobamate, its epilepsy treatment, to the Brazilian market through a distribution agreement with Eurofarma. The move represents a significant step in the South Korean drugmaker's strategy to establish a foothold across Latin America's largest economy.

The company's CEO participated in South Korean President Lee Jae Myung's economic delegation to Brazil, becoming the first pharmaceutical or biotechnology executive from Korea to join such a mission. SK Biopharmaceuticals was the sole representative from Korea's pharma and biotech sectors on the trip.

Strategic Market Entry

According to SK Biopharmaceuticals, the company signed a memorandum of understanding with Eurofarma, one of Brazil's leading pharmaceutical distributors. The partnership will enable Cenobamate to reach Brazilian patients through established distribution networks already serving the country's healthcare system.

Brazil's epilepsy patient population numbers in the millions, making it a critical market for specialized neurological treatments. The country's public and private healthcare systems have been expanding access to newer-generation anticonvulsants, creating opportunities for international pharmaceutical companies with proven products.

Cenobamate has gained regulatory approvals in multiple markets since its initial launch. The drug targets focal-onset seizures, one of the most common forms of epilepsy in adults. Clinical data has shown efficacy rates that position it competitively against existing treatments in the therapeutic category.

Regional Ambitions

The Brazil launch follows SK Biopharmaceuticals' earlier entries into other Latin American territories. The company has been methodically building its presence across the region, targeting countries with substantial patient populations and healthcare infrastructure capable of supporting specialized neurological care.

Latin America represents a growth frontier for Asian pharmaceutical companies seeking to diversify beyond saturated North American and European markets. Brazil, with its population of over 200 million and expanding middle class, offers both scale and purchasing power that smaller regional markets cannot match.

Eurofarma brings decades of experience navigating Brazil's complex regulatory environment and fragmented distribution landscape. The company operates manufacturing facilities across Latin America and maintains relationships with both public procurement agencies and private hospital networks.

Presidential Trade Diplomacy

The presidential economic delegation to Brazil included executives from multiple Korean industries, with SK Biopharmaceuticals representing the life sciences sector. Such delegations typically aim to open doors for commercial agreements and signal government support for export-oriented industries.

Korea's pharmaceutical exports have grown steadily over the past decade, driven by both finished drugs and active pharmaceutical ingredients. The government has identified biotechnology and specialty pharmaceuticals as strategic sectors worthy of diplomatic and financial support.

SK Biopharmaceuticals' inclusion in the delegation underscores the company's growing profile within Korea's export economy. The firm has transitioned from a research-focused operation to a commercial-stage company with products generating revenue across multiple continents.

Market Dynamics

Brazil's pharmaceutical market has been consolidating, with local players partnering with international companies to access novel therapies. Eurofarma itself has pursued similar arrangements with European and North American drugmakers, providing a template for the SK Biopharmaceuticals collaboration.

Pricing and reimbursement negotiations in Brazil can extend over months, particularly for products seeking inclusion in the national health system's formulary. Private insurance coverage often moves faster, creating a two-tier market entry pathway that companies typically pursue in parallel.

The epilepsy treatment segment in Brazil has historically relied on generic versions of older anticonvulsants. Newer drugs face the challenge of demonstrating sufficient clinical advantage to justify premium pricing, a hurdle SK Biopharmaceuticals will need to clear as it introduces Cenobamate.

Operational Implications

SK Biopharmaceuticals will need to establish medical affairs and pharmacovigilance operations in Brazil to support the product launch. Regulatory requirements mandate local safety monitoring and adverse event reporting, functions that typically require in-country personnel or contracted service providers.

The company has not disclosed financial terms of the Eurofarma agreement or projected timelines for commercial availability. Distribution deals in emerging markets often involve milestone payments tied to regulatory approvals and sales thresholds, structures that align partner incentives while managing risk.

Brazil's epilepsy treatment landscape will now include a Korean entrant competing against established brands from US and European pharmaceutical giants. Market share gains will depend on clinical differentiation, pricing strategy, and the strength of Eurofarma's sales force in reaching prescribing neurologists.

The Latin America expansion positions SK Biopharmaceuticals to capture revenue growth outside its core markets while building a geographic portfolio that reduces dependence on any single region. Investors will watch Brazilian sales performance as an indicator of the company's ability to execute in complex emerging markets.